news-24

Dr. Angelo Maria Manzo, our esteemed Senior Business Development Manager at Porton Pharma Solutions Ltd., joins us at BOS Basel 2023! Angelo’s deep industry knowledge and strategic vision are set to make a remarkable impact as he explores new collaborations, identifies growth opportunities, and expands our network. Drop by Stand 17 to catch up with

We are thrilled to announce the establishment of our state-of-the-art Small Molecule Platform in Shanghai, revolutionizing our CDMO services. With this exciting development, Porton Pharma Solutions Ltd. now have seven R&D and production facilities in Shanghai that are equipped to provide comprehensive solutions for drug substance, drug preparation, synthetic macromolecules, and biological macromolecules. As a

Join us in welcoming Dr. Wenfang Miao (Renee) as the new CEO of Porton Pharma Solutions Ltd. USA and J-STAR Research, Inc., and Vice-President of Porton Pharma Solutions, LTD. Dr. Miao brings with her more than 25 years of experience in technical, operational, and strategic leadership within the pharmaceutical industry as she will navigate Porton’s

Our very own Serge Kechichian is all set to tee it up for a cause with colleagues, suppliers, and customers in support of the DCAT (Drug, Chemical & Associated Technologies Association) Scholarship Golf Outing. Under DCAT’s Science and Scholarship Committee’s scholarship program, the event will be held on June 26 at TPC Jasna Polana in

Join J-STAR Research, Inc. Executive Director of Computational Chemistry and Data Science, Yuriy Abramov, Ph.D., as he takes the stage as an invited speaker at the 6th David Grand Symposium on June 15. He will share his insights on computational studies on the crystallization development and characterization of pharmaceutical crystals, and engage in meaningful discussions

On May 8, 2023, Porton Pharma Solutions Ltd. (stock code: 300363) celebrated the grand opening of its Small Molecule Business Platform Headquarters, located in Minhang Economic and Technological Development Zone, Shanghai. This momentous event attracted nearly 200 representatives ranging from local government, customers, investors, and academia. Mr. Yujian Chen, Secretary of Shanghai Minhang District, Mr.

On April 11, 2023, Shanghai Porton Nova Biologics, Ltd., a wholly-owned subsidiary of Porton Pharma Solutions Ltd., officially launched the construction of its biologics R&D and manufacturing site in the Waigaoqiao Free Trade Zone of Pudong New Area, Shanghai, China. As an important link in Porton’s strategic new capability building, the site will provide one-stop

Porton Pharma Solutions Ltd. recently released 2022 CSR Report which is its seventh CSR report since IPO. This report demonstrates the company’s ideas and achievements in fulfilling social responsibility from aspects such as “improving corporate governance”, “providing high-quality services”, “empowering employee development”, “practicing green development”, and “participating in community co-development”. Portonisalways committed to sustainable development，adopting